EPO Decision To Grant European Patent For Rencofilstat Further Strengthens Hepion's Patent Portfolio
EPO Decision To Grant European Patent For Rencofilstat Further Strengthens Hepion's Patent Portfolio
– Patent Covers 38 European Countries –
— 专利覆盖 38 个欧洲国家 —
– Rencofilstat's Exclusivity May Extend into 2048 –
— Rencofilstat 的独家经营权可能会延续到 2048 年 —
EDISON, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH"), fibrotic diseases, hepatocellular carcinoma ("HCC"), and other chronic diseases, today announced that the European Patent Office ("EPO") has granted European Patent No. EP 3886813, covering the innovative formulation of Hepion's lead cyclophilin inhibitor, rencofilstat.
新泽西州爱迪生，2023年3月2日（GLOBE NEWSWIRE）——Hepion Pharmicals, Inc.（纳斯达克股票代码：HEPA），一家临床阶段的生物制药公司，专注于人工智能（“AI”）驱动的治疗药物开发，用于治疗非酒精性脂肪性肝炎（“NASH”）、纤维化疾病、肝细胞癌（“HCC”）和其他慢性病，今天宣布，欧洲专利局（“EPO”）已授予欧洲专利号EP 3886813，涵盖了Hepion的主要亲环素抑制剂rencofilstat的创新配方。
The newly granted European patent also significantly extends the time period of Hepion's patent exclusivity for rencofilstat. The Company's original composition-of-matter patent estate, comprising 52 patents issued in every major market throughout the world, are expected to provide exclusivity to 2036. The newly granted rights, which will encompass 38 European countries, are expected to extend the drug candidate's patent life by approximately eight years, to 2044. Additional filings are also underway to potentially extend composition-of-matter and method-of-manufacturing exclusivity until 2048. In addition to the indications covered in the original composition-of-matter patents (viral, cardiovascular, neurological, and inflammatory diseases), Hepion has also filed various method-of-use patent applications covering a variety of additional indications (fibrosis, cancer, and thrombosis).
新授予的欧洲专利还大大延长了Hepion对rencofilstat的专利独有期限。该公司最初的物质组成专利包括在全球每个主要市场颁发的52项专利，预计将在2036年之前提供独家经营权。新授予的权利将涵盖38个欧洲国家，预计将把候选药物的专利期限延长约八年，至2044年。其他申请也在进行中，以有可能将物质组成和制造方法的专有性延长至2048年。除了原始物质组成专利中涵盖的适应症（病毒、心血管、神经系统和炎症性疾病）外，Hepion还提交了涵盖各种其他适应症（纤维化、癌症和血栓形成）的各种使用方法专利申请。
Robert Foster, PharmD, PhD, Hepion's Chief Executive Officer, stated, "Rencofilstat is very challenging to formulate, owing to the physical-chemical properties of the molecule. Nevertheless, as awareness of its potential to address a number of significant unmet medical needs across a variety of indications continues to grow amongst researchers and drug developers in global markets, it is important this opportunity is well protected. To that end, our expanding intellectual property estate, including this new European patent, should ensure that rencofilstat has long-term market exclusivity."
Hepion首席执行官PharmD、Hepion首席执行官罗伯特·福斯特博士表示：“由于该分子的物理化学特性，Rencofilstat的配方非常具有挑战性。尽管如此，随着全球市场研究人员和药物开发人员对它有可能解决各种适应症中许多未得到满足的重大医疗需求的认识不断提高，妥善保护这一机会非常重要。为此，我们不断扩大的知识产权，包括这项新的欧洲专利，应确保rencofilstat具有长期的市场独家经营权。”
译文内容由第三方软件翻译。